Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease Clinical trials frequently include multiple ...
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel ...
SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on ...
Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant ...
Tarlatamab showed promising antitumor activity in heavily pretreated SCLC patients, including those with untreated brain metastases. Real-world data indicated higher rates of CRS and ICANS compared to ...
In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% ...
FOG-001, the first and only direct β-catenin:TCF inhibitor, shows early clinical activity in a range of Wnt/β-catenin–driven tumors — reinforcing clinical development opportunities across both rare ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced ...
Leveraging the Rural-Urban Commuting Area Tool to Address Geographic Disparities in Cancer Care: A Dual-Application Framework for Institutional and National Initiatives We adapted an established ...
Valerio Therapeutics is ending all clinical trials, including an ongoing phase 1/2 study for its investigational “DNA decoy” candidate designed to treat recurrent solid tumors. The Paris-based biotech ...
Physical activity supports the same brain systems targeted in clinical treatment”— Dr. Stanford Owen GULFPORT, LA, ...